Opinion|Videos|May 26, 2025
Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay on ALK inhibitor therapy to realize long-term benefits.
Advertisement
Episodes in this series
ALK Inhibitor Therapy Management
Main Discussion Topics
- Patient education strategies for lorlatinib therapy adherence
- Lipid-lowering interventions to support long-term lorlatinib treatment
- Monitoring tools for patients on ALK inhibitors
- Patient education methodologies specific to ALK inhibitor therapy
Discussion Questions Posed
- Grizzard inquired about proactive patient education and lipid-lowering interventions to help patients maintain lorlatinib therapy for long-term benefits
Castronovo asked about potentially useful tools for educating and monitoring patients on ALK inhibitors
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Inside the CAR T-Cell Therapy Process for CLL
5